Schering-Plough
is a
pharmaceutical company committed to discovering, developing
and marketing new therapies and treatment programs that can improve people’s
health and extend lives. The company is a recognized leader in
biotechnology, genomic and gene therapy. Core Production groups are allergy
and respiratory, anti-infective and anticancer, cardiovascular and dermatological.
In addition to our 3 existing manufacturing plants in Singapore, we are building 3 additional plants and an R&D facility; bringing our total investments to US$730 million. This makes SP one of the largest pharmaceutical investors in Singapore. Our plants in Singapore manufacture a range of active pharmaceutical ingredients as well as final product forms such as inhalers, sterile biological products and tablets.
